PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial

•Results of ENGOT HRD initiative on 468 shared FFPE samples of the PAOLA-1 trial.•Academic Leuven HRD test shows comparable results with Myriad MyChoice HRD test.•Leuven HRD test confirms the impact of olaparib on PFS and OS in the HRD+ patients.